Research Report for Investors: CRISPR Therapeutics AG (CRSP)

amazon quarterly result

CRISPR Therapeutics AG (CRSP) belonging to the Healthcare sector has surged 0.11% and closed its last trading session at $69.65.

The company reported its EPS on 12/30/2017. Currently, the stock has a 1 Year Price Target of $63.38.

The consensus recommendation, according to Zacks Investment research, is 1.57. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 1.57 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.57 and 1.67 respectively.

CRISPR Therapeutics AG on 12/30/2017 reported its EPS as $-0.54 with the analysts projecting the EPS of the stock as $-0.61. The company beat the analyst EPS Estimate with the difference of $0.07. This shows a surprise factor of 0.115%.

Many analysts have provided their estimated foresights on CRISPR Therapeutics AG Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.67.

Whereas they predicted High and Low Earnings Estimate as $-0.6 and $-0.74 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.54.

Analysts are also projecting an Average Revenue Estimate for CRISPR Therapeutics AG as $2510 in the Current Quarter. This estimate is provided by 6 analysts.

CRISPR Therapeutics AG (CRSP) has the market capitalization of $3.32 Billion. The company rocked its 52-Week High of $73.9 and touched its 52-Week Low of $13.5.

The stock has Return on Assets (ROA) of -24.4 percent. Return on Equity (ROE) stands at -35.2% and Return on Investment (ROI) of -32 percent.

The stock is currently showing YTD performance of 196.64 Percent. The company has Beta Value of 0 and ATR value of 4.35. The Weekly and Monthly Volatility stands at 7.87% and 7.24%.